AXIM BIOTECHNOLOGIES, INC. Operating Income Loss

Quick Answer

AXIM BIOTECHNOLOGIES, INC. reported Operating Income Loss of -$2.75 million for the year ending 2023.

  • AXIM BIOTECHNOLOGIES, INC. showed an increase of +40.9% in Operating Income Loss from 2022 to 2023.
  • This data is from AXIM BIOTECHNOLOGIES, INC.'s annual report (Form 10-K), filed with the SEC on April 16, 2024.
  • XBRL data for this metric is available from 2016 to 2023 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2016 to 2023), AXIM BIOTECHNOLOGIES, INC.'s Operating Income Loss has grown by 26.8%.
  • Historical annual values: Fiscal year 2023: -$2.75 million | Fiscal year 2022: -$4.65 million | Fiscal year 2021: -$13.97 million | Fiscal year 2018: -$5.04 million | Fiscal year 2017: -$3.15 million | Fiscal year 2016: -$3.76 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: